News

The first study of the phase III program will assess an intermittent dosage regimen of cetrorelix as a potential safe and tolerable treatment providing prolonged improvement in benign

As part of the agreement, Novacea will gain the rights for the worldwide development and commercialization of AQ4N. KuDOS said that it anticipates the completion of patient recruitment

The company also commented that the database for the North American phase III clinical trial for Alzhemed has been locked, which means that Neurochem has finished collecting data

Antisoma believes the deal will provide it with extra resources it can use to further expand its pipeline and to exploit the value in its present portfolio. The

Results from the study, show that over five years there is one extra case of ovarian cancer in every 2,500 women who take HRT. And for every 3,300

Vical has provided Vaxfectin to researchers for several years, and data have been published showing evidence of increased immunogenicity and protective efficacy of DNA vaccines against diseases including

The anti-IgE immunotherapy, RP01, is designed to induce the immune system to produce antibodies that block Immunoglobulin E (IgE), the key mediator of an allergic response. The primary

PDX has already been awarded orphan drug designation by the FDA for the treatment of patients with T-cell lymphoma in July 2006. The orphan medicinal product designation is

The compound, TRA-SCH 530348, is being evaluated to determine whether it has the potential to provide clinical benefit without the additional bleeding liabilities often found in current therapies.